ONCO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/B is low, but this is typical for companies facing bankruptcy where assets are impaired.
- Extremely low P/B (0.02)
- No Graham Number available
- Value trap characteristics
- Negative earnings
Growth rates are deeply negative across all primary metrics.
- Small Q/Q EPS improvement
- Revenue growth -57.40%
- Negative forward P/E
- No analyst coverage
Historical price performance is a textbook 'death spiral'.
- 1Y Change -97.2%
- 6M Change -95.7%
- 1M Change -70.5%
Piotroski score of 1/9 confirms the company is in the weakest possible health tier.
- Low Debt/Equity
- Piotroski F-Score 1/9
- Current Ratio 0.66
- ROE -115.46%
Company is not in a position to return capital.
- No dividend
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ONCO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ONCO
Onconetix, Inc.
Primary
|
-100.0% | -100.0% | -97.2% | -95.7% | -70.5% | -32.6% |
|
ADTX
Aditxt, Inc.
Peer
|
-100.0% | -100.0% | -100.0% | -99.8% | -67.1% | -51.2% |
|
LYRA
Lyra Therapeutics, Inc.
Peer
|
-99.9% | -99.5% | -87.8% | -91.8% | -50.8% | +32.6% |
|
NIVF
NewGenIvf Group Limited
Peer
|
-100.0% | -100.0% | -99.8% | -98.0% | -6.4% | +9.4% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -100.0% | -96.4% | -95.4% | -13.6% | -6.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ONCO
Onconetix, Inc.
|
BEARISH | $0.55M | - | -115.5% | -% | $0.76 | |
|
ADTX
Aditxt, Inc.
|
BEARISH | $0.4M | - | -% | -% | $1.82 | Compare |
|
LYRA
Lyra Therapeutics, Inc.
|
BEARISH | $1.15M | - | -6595.0% | -% | $0.65 | Compare |
|
NIVF
NewGenIvf Group Limited
|
BEARISH | $1.25M | 0.06 | 79.4% | 209.0% | $2.19 | Compare |
|
AKAN
Akanda Corp.
|
BEARISH | $1.73M | 0.01 | -60.9% | -266.3% | $0.82 | Compare |
Past News Coverage
Recent headlines mentioning ONCO from our newsroom.